P1Y0000002259427190001649989--09-302022Q3false176461628004500000.580000020000000016499892021-11-300001649989us-gaap:MeasurementInputSharePriceMembe...
Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S...
ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under...
ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial...
Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional...
0001649989 false 0001649989 2022-06-02 2022-06-02 iso4217:USD xbrli:shares...
0001649989 false 0001649989 2022-05-31 2022-05-31 iso4217:USD xbrli:shares...
ISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial...
ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial...
P1Y0000002257927420001649989--09-302022Q2false176461628004500000.58000002000000001649989us-gaap:MeasurementInputSharePriceMember2022-03-31000164998...
0001649989 false 0001649989 2022-05-13 2022-05-13 iso4217:USD xbrli:shares...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.